OBJECTIVES/HYPOTHESIS: To determine posttreatment quality of life (QOL) in head and neck cancer patients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. STUDY DESIGN: Retrospective study. METHODS: One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. RESULTS: Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. CONCLUSION: The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: To determine posttreatment quality of life (QOL) in head and neck cancerpatients, stratifying by human papillomavirus (HPV)/p16 status and primary treatment modality. STUDY DESIGN: Retrospective study. METHODS: One hundred and seventy-seven patients (N=177) with head and neck squamous cell carcinoma and known HPV/p16 status were included. All patients completed at least one baseline or posttreatment University of Washington QOL survey. QOL scores were averaged and compared across patients, stratifying by HPV/p16 status and primary treatment modality (surgical vs. nonsurgical). In the analysis, p16 was used as a surrogate marker for HPV. RESULTS: Of the 177 patients, 80 (45.2%) were p16-positive and 49.7% of subsites were oropharyngeal. Nearly 60% (105/177) of patients underwent primary surgery, 26.7% (28/105) of patients with transoral robotic or laser techniques. The remainder 40.7% of patients underwent primary radiation and/or chemotherapy. Overall, QOL scores were better for p16-positive patients compared to p16-negative patients at baseline (P=0.008), at 6 months posttreatment (P=0.034), and at greater than 1 year posttreatment (P=0.013). P16-positive patients had better QOL scores in speech (P=0.0009), chewing (P=0.0004), and swallowing (P=0.021) after 1 year posttreatment compared to p16-negative patients. Primary treatment modality did not affect overall QOL or any of the 12 QOL categories in p16-positive patients at any time point. At over 1 year posttreatment, QOL was at or above baseline in both p16-positive treatment groups. CONCLUSION: The p16-positive patients had better baseline and posttreatment overall QOL compared to p16-negative patients. The overall and category specific QOL scores for p16-positive patients were not affected by primary treatment modality. LEVEL OF EVIDENCE: 4.
Authors: K Aro; L Bäck; V Loimu; K Saarilahti; S Rogers; H Sintonen; R Roine; Antti Mäkitie Journal: Eur Arch Otorhinolaryngol Date: 2015-07-28 Impact factor: 2.503
Authors: Kara S Davis; Chwee Ming Lim; David A Clump; Dwight E Heron; James P Ohr; Seungwon Kim; Umamaheswar Duvvuri; Jonas T Johnson; Robert L Ferris Journal: Head Neck Date: 2015-12-17 Impact factor: 3.147
Authors: Ryan P Goepfert; Jan S Lewin; Martha P Barrow; C David Fuller; Stephen Y Lai; Juhee Song; Brian P Hobbs; G Brandon Gunn; Beth M Beadle; David I Rosenthal; Adam S Garden; Merrill S Kies; Vali A Papadimitrakopoulou; David L Schwartz; Katherine A Hutcheson Journal: Laryngoscope Date: 2016-07-21 Impact factor: 3.325
Authors: S N Rogers; R S Pinto; J Lancaster; F Bekiroglu; D Lowe; S Tandon; T M Jones Journal: Eur Arch Otorhinolaryngol Date: 2016-04-18 Impact factor: 2.503